Emergent Biosolutions, Inc. (EBS) Stock Price

EBSStock

$6.38−32.13%52W

Market Cap$327.12M

P/E6.22x

PEG Ratio0.38

Div yield—

Beta2.42

EBS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-36.23%

Price vs S&P 500 (4W)-1.27%

PEG Ratio0.38

VGM Score52.02

P/E Ratio (Annual)6.22x

P/CF (Annual)1.92x

Book Value / Share (Quarterly)$6.66

P/TBV (Annual)7.54x

Revenue Growth (3Y)-12.81%

Cash Flow / Share (Quarterly)$0.69

Price vs S&P 500 (YTD)-60.31%

Gross Margin (TTM)55.84%

Net Profit Margin (TTM)-22.96%

EPS (TTM)$-3.51

10-Day Avg Trading Volume1.26M

EPS Excl Extra (TTM)$-3.51

Revenue Growth (5Y)-13.74%

EPS (Annual)$0.93

ROI (Annual)4.80%

Gross Margin (Annual)56.09%

Net Profit Margin (5Y Avg)-18.06%

Cash / Share (Quarterly)$2.72

P/E Basic Excl Extra (TTM)9.41x

Revenue Growth QoQ (YoY)66.29%

EPS Growth (5Y)-30.38%

P/E Normalized (Annual)6.22x

ROA (Last FY)3.99%

Revenue Growth TTM (YoY)-9.56%

EBITD / Share (TTM)$-0.37

ROE (5Y Avg)-29.65%

Operating Margin (TTM)-11.23%

Cash Flow / Share (Annual)$3.01

P/B Ratio0.96x

P/B Ratio (Quarterly)1.27x

Net Income / Employee (Annual)$58,400

EV / Revenue (TTM)1.00x

Net Interest Coverage (TTM)2.40x

ROA (TTM)-13.56%

EPS Growth QoQ (YoY)-89.85%

EV / EBITDA (TTM)6.11x

EPS Incl Extra (Annual)$0.93

Current Ratio (Annual)5.01x

Quick Ratio (Quarterly)2.74x

3-Month Avg Trading Volume1.11M

52-Week Price Return-32.13%

EV / Free Cash Flow (Annual)4.91x

P/E Incl Extra (TTM)9.41x

Revenue / Employee (TTM)$855,800

Tangible BV / Share (Quarterly)$1.55

P/S Ratio (Annual)0.44x

Asset Turnover (Annual)0.56x

52-Week High$14.06

Operating Margin (5Y Avg)-10.91%

EPS Excl Extra (Annual)$0.93

CapEx CAGR (5Y)-38.03%

Tangible BV CAGR (5Y)-24.31%

26-Week Price Return-26.33%

Quick Ratio (Annual)2.22x

13-Week Price Return-16.38%

Total Debt / Equity (Annual)1.09x

Current Ratio (Quarterly)5.42x

Enterprise Value$769.22M

Revenue / Share Growth (5Y)-14.64%

Asset Turnover (TTM)0.59x

Book Value / Share Growth (5Y)-18.12%

Revenue / Employee (Annual)$825,400

Inventory Turnover (Annual)1.00x

Pretax Margin (Annual)11.15%

Cash / Share (Annual)$3.94

3-Month Return Std Dev86.46%

Gross Margin (5Y Avg)43.73%

Net Income / Employee (TTM)$-196,400

EBITDA CAGR (5Y)-20.88%

EBITDA Interim CAGR (5Y)-24.53%

ROE (Last FY)10.07%

Net Interest Coverage (Annual)-1.87x

EPS Basic Excl Extra (Annual)$0.93

P/FCF (TTM)4.23x

Receivables Turnover (TTM)5.71x

EV / Free Cash Flow (TTM)21.67x

Total Debt / Equity (Quarterly)1.70x

EPS Incl Extra (TTM)$-3.51

Receivables Turnover (Annual)6.22x

ROI (TTM)-16.22%

P/S Ratio (TTM)0.42x

Pretax Margin (5Y Avg)-14.97%

Revenue / Share (Annual)$13.10

Tangible BV / Share (Annual)$1.65

Forward P/E17.74x

Free OCF CAGR (5Y)-16.44%

Price vs S&P 500 (52W)-47.66%

P/E Ratio (TTM)9.41x

Year-to-Date Return-48.38%

5-Day Price Return-8.60%

EPS Normalized (Annual)$0.93

ROA (5Y Avg)-10.14%

Net Profit Margin (Annual)7.08%

Month-to-Date Return-3.33%

Cash Flow / Share (TTM)$-9.38

EBITD / Share (Annual)$2.70

Operating Margin (Annual)11.83%

LT Debt / Equity (Annual)1.09x

P/CF (TTM)3.35x

ROI (5Y Avg)-12.17%

P/E Excl Extra (TTM)9.41x

LT Debt / Equity (Quarterly)1.70x

EPS Basic Excl Extra (TTM)$-3.51

P/TBV (Quarterly)5.43x

P/B Ratio (Annual)1.24x

Inventory Turnover (TTM)1.06x

Pretax Margin (TTM)-18.96%

Book Value / Share (Annual)$10.03

Price vs S&P 500 (13W)-19.07%

Net Margin Growth (5Y)-18.44%

Beta2.42x

P/FCF (Annual)2.09x

Revenue / Share (TTM)$14.93

ROE (TTM)-35.91%

52-Week Low$4.36

vGradeA

gGradeD

mGradeC

vgmGradeC

EBS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.11	$0.60	+445.45%(+$0.49)
Q1 2026	Apr 30, 2026	-$0.25	$0.21	+184.00%(+$0.46)
Q4 2025	Feb 26, 2026	$0.11	-$0.43	-490.91%(-$0.54)
Q3 2025	Oct 29, 2025	-$0.12	$1.06	+984.22%(+$1.18)
Q2 2025	Aug 6, 2025	-$0.49	$0.16	+132.73%(+$0.65)

EBS Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

3.71

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
EBSEmergent Biosolutions, Inc.	A	D	C	0.4x	-9.6%	55.8%	-30.4%	$6.38
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Emergent Biosolutions, Inc.

Emergent BioSolutions develops and manufactures pharmaceutical products and medical countermeasures for public health markets. The company operates three main segments: commercial respiratory products including NARCAN and KLOXXADO nasal sprays; government-contracted medical countermeasures such as anthrax and smallpox vaccines; and bioservices. Revenue is primarily derived from the U.S. market.

EBS Next Earnings Report

Report dateNov 2, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$0.39

Revenue estimate$123.20M

Also reporting on Nov 2, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

EBS Insider Transactions

SellOct 7, 2026
DEGOLYER DONALD W
Director
Shares: 17,800Value: $126,202
SellOct 1, 2026
WILLIAMS PAUL ANTHONY
Officer
Shares: 3,000Value: $19,590

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for October 2026

Companies in Related Industries

KYTXKyverna Therapeutics, Inc. Common StockBiological Products
FENCFennec Pharmaceuticals Inc. Common StockBiological Products
CCCCC4 Therapeutics, Inc.Biological Products
ASPIASP Isotopes Inc. Common StockIndustrial Chemicals
NLNLI Holdings, Inc.Industrial Chemicals
CGCCanopy Growth Corporation Common SharesPharmaceutical Preparations
SNDLSundial Growers Inc. Common SharesPharmaceutical Preparations
OECOrion S.A.Industrial Chemicals

Same SIC sector, outside this company's own industry.

Analyst Sentiment

3.7

Buy

Consensus rating

52-Week Range

Low$4.36

High$14.06